NCT06568172 2026-03-19
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
8 trialsNCT04708418 2026-03-18
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07144384 2026-02-13
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT01005745 2025-12-19
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT03567889 2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3 Recruiting
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT06295809 2025-12-09
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Active not recruiting
NCT07094685 2025-11-25
SENIOR-HN
University of Michigan Rogel Cancer Center
Phase 2 Recruiting